268 related articles for article (PubMed ID: 27653520)
21. Arm swing as a potential new prodromal marker of Parkinson's disease.
Mirelman A; Bernad-Elazari H; Thaler A; Giladi-Yacobi E; Gurevich T; Gana-Weisz M; Saunders-Pullman R; Raymond D; Doan N; Bressman SB; Marder KS; Alcalay RN; Rao AK; Berg D; Brockmann K; Aasly J; Waro BJ; Tolosa E; Vilas D; Pont-Sunyer C; Orr-Urtreger A; Hausdorff JM; Giladi N
Mov Disord; 2016 Oct; 31(10):1527-1534. PubMed ID: 27430880
[TBL] [Abstract][Full Text] [Related]
22. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
23. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
24. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Thaler A; Artzi M; Mirelman A; Jacob Y; Helmich RC; van Nuenen BF; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Hendler T; Giladi N; Ben Bashat D;
Mov Disord; 2014 May; 29(6):823-7. PubMed ID: 24482120
[TBL] [Abstract][Full Text] [Related]
25. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
[TBL] [Abstract][Full Text] [Related]
26. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
[TBL] [Abstract][Full Text] [Related]
27. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
28. Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
Anderkova L; Barton M; Rektorova I
Mov Disord; 2017 Jun; 32(6):917-922. PubMed ID: 28256044
[TBL] [Abstract][Full Text] [Related]
29. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
[TBL] [Abstract][Full Text] [Related]
30. Connectivity of corticostriatal circuits in nonmanifesting LRRK2 G2385R and R1628P carriers.
Zhang D; Yao J; Ma J; Gao L; Sun J; Fang J; He H; Wu T
CNS Neurosci Ther; 2022 Dec; 28(12):2024-2031. PubMed ID: 35934920
[TBL] [Abstract][Full Text] [Related]
31. Anatomical and functional correlates of persistent pain in Parkinson's disease.
Polli A; Weis L; Biundo R; Thacker M; Turolla A; Koutsikos K; Chaudhuri KR; Antonini A
Mov Disord; 2016 Dec; 31(12):1854-1864. PubMed ID: 27704616
[TBL] [Abstract][Full Text] [Related]
32. Functional connectivity underpinnings of fatigue in "Drug-Naïve" patients with Parkinson's disease.
Tessitore A; Giordano A; De Micco R; Caiazzo G; Russo A; Cirillo M; Esposito F; Tedeschi G
Mov Disord; 2016 Oct; 31(10):1497-1505. PubMed ID: 27145402
[TBL] [Abstract][Full Text] [Related]
33. Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study.
Ning B; Guo G; Gu C; Xu J; Bibic A; He X; Liu H; Chen L; Wei Z; Duan W; Liu P; Lu H; van Zijl PCM; Ross CA; Smith W; Hua J
Neurodegener Dis; 2020; 20(2-3):65-72. PubMed ID: 33152738
[TBL] [Abstract][Full Text] [Related]
34. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
[TBL] [Abstract][Full Text] [Related]
35. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
Correia Guedes L; Reimão S; Paulino P; Nunes RG; Bouça-Machado R; Abreu D; Gonçalves N; Soares T; Fabbri M; Godinho C; Pita Lobo P; Neutel D; Quadri M; Coelho M; Rosa MM; Campos J; Outeiro TF; Sampaio C; Bonifati V; Ferreira JJ
Mov Disord; 2017 Sep; 32(9):1331-1333. PubMed ID: 28686310
[No Abstract] [Full Text] [Related]
36. Clinical Features of LRRK2 Carriers with Parkinson's Disease.
Kestenbaum M; Alcalay RN
Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277
[TBL] [Abstract][Full Text] [Related]
37. Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.
Thaler A; Gonen T; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Bloem BR; Giladi N; Hendler T;
Brain Imaging Behav; 2019 Aug; 13(4):1009-1020. PubMed ID: 29971685
[TBL] [Abstract][Full Text] [Related]
38. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
39. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
40. Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease.
Ham JH; Cha J; Lee JJ; Baek GM; Sunwoo MK; Hong JY; Shin NY; Sohn YH; Lee JM; Lee PH
Neuroimage; 2015 Oct; 119():296-304. PubMed ID: 26143204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
